https://orcid.org/0000-0003-1932-6345
References
- Sun W, Liu Y, Amanat F, González-Domínguez I, McCroskery S, Slamanig S, Coughlan L, Rosado V, Lemus N, Jangra S, et al. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nat Commun. 2021;12(1):6197. doi:10.1038/s41467-021-26499-y.
- Sun W, McCroskery S, Liu W-C, Leist SR, Liu Y, Albrecht RA, Slamanig S, Oliva J, Amanat F, Schäfer A, et al. A Newcastle disease virus (NDV) expressing a membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine. Vaccines. 2020;8(4):771. doi:10.3390/vaccines8040771.
- Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K, Le KC, Wrapp D, Lee AG, Liu Y, et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. 2020 Sep 18;369(6510):1501–6. doi:10.1126/science.abd0826. Epub 2020 Jul 23. PMID: 32703906; PMCID: PMC7402631.
- Duc Dang A, Dinh Vu T, Hai Vu H, Thanh Ta V, Thi Van Pham A, Thi Ngoc Dang M, Van Le B, Huu Duong T, Van Nguyen D, Lawpoolsri S, et al. Safety and immunogenicity of an egg-based inactivated newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Vaccine. 2022;40(26):3621–32. doi:10.1016/j.vaccine.2022.04.078.
- Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul S, Sivakorn C, Narakorn P, Surichan S, Prangpratanporn S, Puksuriwong S, et al. Safety and immunogenicity of an inactivated recombinant newcastle disease virus vaccine expressing SARS-CoV-2 spike: interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine. 2022;45:101323. doi:10.1016/j.eclinm.2022.101323.
- Campbell JD. Development of the CpG adjuvant 1018: a case study. In: Fox CB, editor. Vaccine adjuvants. Vol. 1494. New York: Springer; 2017. p. 15–27.
- Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W-T, Limbo O, Smith C, Song G, Woehl J, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956–63. doi:10.1126/science.abc7520.
- McAdams D, Lakatos K, Estrada M, Chen D, Plikaytis B, Sitrin R, White JA. Quantification of trivalent non-replicating rotavirus vaccine antigens in the presence of aluminum adjuvant. J Immunol Methods. 2021;494:113056. doi:10.1016/j.jim.2021.113056.
- Ter Meulen J, van den Brink EN, Poon LLM, Marissen WE, Leung CSW, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3(7):e237. doi:10.1371/journal.pmed.0030237.